结直肠癌中肿瘤分级与肿瘤出芽是否等同?771例回顾性分析
该回顾性研究纳入771例结直肠癌患者,评估WHO 2010肿瘤分级(G1-G3)与肿瘤出芽(BD1-BD3,分别对应每0.785 mm² 0-4、5-9、≥10个出芽)的相关性及对预后的影响。结果显示两者虽相关(p<0.0001,一致率33.8%)但临床病理关联不同,仅高肿瘤出芽与更差的总生存(p=0.0286)和无病生存(p=0.001)相关,多因素分析中出芽独立于分级。
要点
- 肿瘤分级与出芽相关但一致率仅33.8%,属不同生物学特征。
- 仅高肿瘤出芽与更差总生存和无病生存相关,分级无此关联。
- 多因素分析中肿瘤出芽独立于肿瘤分级预测无病生存。
核心结论
- 肿瘤分级与肿瘤出芽是反映不同生物学过程的独立特征,出芽在预测无病生存方面优于分级。
研究设计与样本
- 回顾性队列研究,纳入771例结直肠癌患者,评估肿瘤分级(WHO 2010 G1-G3)与肿瘤出芽(BD1-BD3)的相关性及预后影响。
主要发现
- 肿瘤分级与出芽相关(p<0.0001,一致率33.8%),但18.1%的BD1病例为G3,仅2例BD3为G1。
- 高分级和高出芽均与更高pT、淋巴结转移、远处转移及淋巴管和血管侵犯相关(p<0.01)。
- 仅肿瘤分级额外与右半结肠位置和黏液组织学相关。
- 高出芽导致更差的总生存(p=0.0286)和无病生存(p=0.001),而分级无此关联。
- 多因素分析中出芽独立于肿瘤分级。
关键数值与推荐
- 肿瘤出芽分级:BD1为每0.785 mm² 0-4个出芽,BD2为5-9个,BD3为≥10个。
- 肿瘤分级采用WHO 2010标准:G1、G2、G3。
临床怎么用
- 在结直肠癌病理评估中应关注肿瘤出芽,其预后价值可能优于传统肿瘤分级。
局限性
- 回顾性研究设计可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour grade is traditionally considered in the management of patients with colorectal cancer. However, a large body of literature suggests that a related feature, namely tumour budding, may have a more important clinical impact. The aim of our study is to determine the correlation between tumour grade and tumour budding and their impact on patient outcome. METHODS: A retrospective collective of 771 patients with colorectal cancer were included in the study. Clinicopathological information included tumour grade (World Health Organisation 2010; G1, G2 and G3) and tumour budding evaluated as BD1, BD2 and BD3 and representing 0-4 buds, 5-9 buds and 10 or more buds per 0.785 mm2, respectively. RESULTS: Tumour grade and tumour budding were correlated (p < 0.0001, percent concordance: 33.8%). Of the BD1 cases, 18.1% were of G3. Only two BD3 cases were G1. Both high tumour grade and tumour budding were associated with higher pT, lymph node metastasis, distant metastasis and lymphatic and venous vessel invasion (p < 0.01, all), but only tumour grade was additionally associated with right-sided tumour location and mucinous histology. Higher tumour budding led to worse overall (p = 0.0286) and disease-free survival (p = 0.001), but tumour grade did not. Budding was independent of tumour grade in multivariate analysis. DISCUSSION: Tumour grade and tumour budding are distinct features, as recognised by their different clinicopathological associations, reflecting different underlying biological processes. Nonetheless, tumour budding seems to outperform tumour grade in terms of predicting disease-free survival.
引用
- Zlobec I, Dawson HE, Blank A, et al. Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients. Eur J Cancer. 2020. PMID: 32200222. doi:10.1016/j.ejca.2020.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。